Drug Profile
Insulin aspart faster-acting - Novo Nordisk
Alternative Names: Faster aspart; FIAsp; Fiasp; NN-1218Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 07 Mar 2024 Novo Nordisk completes a phase I trial in Type 2 diabetes mellitus in Hong Kong and Germany (SC, injection) (NCT04698018)
- 25 Apr 2023 Novo Nordisk completes a phase I trial in Type 1 diabetes mellitus in Hong Kong and Germany (SC, injection) (NCT04698018)
- 05 Aug 2022 Novo Nordisk completes a phase III trial in Type 1 diabetes mellitus (Combination therapy) and Type 2 diabetes mellitus (Combination therapy) in China (NCT04588259)